GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (FRA:9VQ) » Definitions » Capex-to-Revenue

Belluscura (FRA:9VQ) Capex-to-Revenue : 5.96 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Belluscura Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Belluscura's Capital Expenditure for the six months ended in Jun. 2023 was €-2.01 Mil. Its Revenue for the six months ended in Jun. 2023 was €0.34 Mil.

Hence, Belluscura's Capex-to-Revenue for the six months ended in Jun. 2023 was 5.96.


Belluscura Capex-to-Revenue Historical Data

The historical data trend for Belluscura's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura Capex-to-Revenue Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
3.27 8.72 - 6.65 3.63

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only - 3.96 1.76 4.89 5.96

Competitive Comparison of Belluscura's Capex-to-Revenue

For the Medical Devices subindustry, Belluscura's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Belluscura's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Belluscura's Capex-to-Revenue falls into.



Belluscura Capex-to-Revenue Calculation

Belluscura's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-4.793) / 1.32
=3.63

Belluscura's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.013) / 0.338
=5.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Belluscura  (FRA:9VQ) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Belluscura Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Belluscura's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Belluscura (FRA:9VQ) Business Description

Traded in Other Exchanges
Address
15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura (FRA:9VQ) Headlines

No Headlines